Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.80
IPXL's Cash to Debt is ranked lower than
67% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. IPXL: 0.80 )
Ranked among companies with meaningful Cash to Debt only.
IPXL' s Cash to Debt Range Over the Past 10 Years
Min: 0.73  Med: 5.00 Max: No Debt
Current: 0.8
Equity to Asset 0.55
IPXL's Equity to Asset is ranked lower than
60% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IPXL: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
IPXL' s Equity to Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.50 Max: 0.82
Current: 0.55
0.12
0.82
Interest Coverage 2.55
IPXL's Interest Coverage is ranked lower than
85% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. IPXL: 2.55 )
Ranked among companies with meaningful Interest Coverage only.
IPXL' s Interest Coverage Range Over the Past 10 Years
Min: 1.51  Med: 286.23 Max: N/A
Current: 2.55
F-Score: 4
Z-Score: 3.01
M-Score: -1.62
WACC vs ROIC
10.63%
4.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 8.08
IPXL's Operating margin (%) is ranked lower than
52% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. IPXL: 8.08 )
Ranked among companies with meaningful Operating margin (%) only.
IPXL' s Operating margin (%) Range Over the Past 10 Years
Min: -23.01  Med: 14.59 Max: 44.72
Current: 8.08
-23.01
44.72
Net-margin (%) 4.53
IPXL's Net-margin (%) is ranked lower than
57% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. IPXL: 4.53 )
Ranked among companies with meaningful Net-margin (%) only.
IPXL' s Net-margin (%) Range Over the Past 10 Years
Min: -24.15  Med: 11.20 Max: 46
Current: 4.53
-24.15
46
ROE (%) 4.01
IPXL's ROE (%) is ranked lower than
60% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. IPXL: 4.01 )
Ranked among companies with meaningful ROE (%) only.
IPXL' s ROE (%) Range Over the Past 10 Years
Min: -26.51  Med: 12.27 Max: 125.75
Current: 4.01
-26.51
125.75
ROA (%) 2.21
IPXL's ROA (%) is ranked lower than
59% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. IPXL: 2.21 )
Ranked among companies with meaningful ROA (%) only.
IPXL' s ROA (%) Range Over the Past 10 Years
Min: -11.98  Med: 7.63 Max: 38.8
Current: 2.21
-11.98
38.8
ROC (Joel Greenblatt) (%) 21.29
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. IPXL: 21.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPXL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -33.28  Med: 40.78 Max: 236.25
Current: 21.29
-33.28
236.25
Revenue Growth (3Y)(%) 12.00
IPXL's Revenue Growth (3Y)(%) is ranked higher than
67% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. IPXL: 12.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPXL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 37.15 Max: 204.1
Current: 12
0
204.1
EBITDA Growth (3Y)(%) -3.10
IPXL's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. IPXL: -3.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPXL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.90 Max: 61.7
Current: -3.1
0
61.7
EPS Growth (3Y)(%) -12.80
IPXL's EPS Growth (3Y)(%) is ranked lower than
76% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. IPXL: -12.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPXL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.5  Med: -6.10 Max: 54.7
Current: -12.8
-32.5
54.7
» IPXL's 10-Y Financials

Financials (Next Earnings Date: 2016-05-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

IPXL Guru Trades in Q2 2015

Steven Cohen 183,000 sh (New)
Chase Coleman 430,000 sh (New)
Alan Fournier 3,204,096 sh (+58.23%)
George Soros Sold Out
Paul Tudor Jones 9,000 sh (-3.23%)
John Hussman 200,000 sh (-20.00%)
NWQ Managers 710,302 sh (-24.12%)
Jim Simons 14,100 sh (-80.39%)
» More
Q3 2015

IPXL Guru Trades in Q3 2015

Kyle Bass 606,618 sh (New)
Paul Tudor Jones 12,300 sh (+36.67%)
Jim Simons Sold Out
Chase Coleman Sold Out
Alan Fournier 3,043,781 sh (-5.00%)
NWQ Managers 596,619 sh (-16.00%)
John Hussman 150,000 sh (-25.00%)
Steven Cohen 59,700 sh (-67.38%)
» More
Q4 2015

IPXL Guru Trades in Q4 2015

Jim Simons 83,800 sh (New)
Joel Greenblatt 19,801 sh (New)
Paul Tudor Jones 21,963 sh (+78.56%)
Samuel Isaly 773,500 sh (unchged)
Kyle Bass Sold Out
Steven Cohen Sold Out
John Hussman Sold Out
Alan Fournier 2,321,581 sh (-23.73%)
NWQ Managers 198,378 sh (-66.75%)
» More
2016

IPXL Guru Trades in 2016

Samuel Isaly 773,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 60.86
IPXL's P/E(ttm) is ranked lower than
80% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. IPXL: 60.86 )
Ranked among companies with meaningful P/E(ttm) only.
IPXL' s P/E(ttm) Range Over the Past 10 Years
Min: 3.95  Med: 19.58 Max: 1032.96
Current: 60.86
3.95
1032.96
Forward P/E 14.39
IPXL's Forward P/E is ranked higher than
51% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. IPXL: 14.39 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 60.86
IPXL's PE(NRI) is ranked lower than
80% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. IPXL: 60.86 )
Ranked among companies with meaningful PE(NRI) only.
IPXL' s PE(NRI) Range Over the Past 10 Years
Min: 3.97  Med: 19.66 Max: 929.67
Current: 60.86
3.97
929.67
Price/Owner Earnings (ttm) 4033.75
IPXL's Price/Owner Earnings (ttm) is ranked lower than
99% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. IPXL: 4033.75 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IPXL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.82  Med: 9.98 Max: 5527.5
Current: 4033.75
2.82
5527.5
P/B 2.14
IPXL's P/B is ranked higher than
59% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. IPXL: 2.14 )
Ranked among companies with meaningful P/B only.
IPXL' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 2.46 Max: 4.3
Current: 2.14
1.32
4.3
P/S 2.65
IPXL's P/S is ranked higher than
51% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. IPXL: 2.65 )
Ranked among companies with meaningful P/S only.
IPXL' s P/S Range Over the Past 10 Years
Min: 1.15  Med: 2.55 Max: 5.73
Current: 2.65
1.15
5.73
PFCF 60.35
IPXL's PFCF is ranked lower than
76% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. IPXL: 60.35 )
Ranked among companies with meaningful PFCF only.
IPXL' s PFCF Range Over the Past 10 Years
Min: 3.84  Med: 12.26 Max: 92.48
Current: 60.35
3.84
92.48
POCF 33.17
IPXL's POCF is ranked lower than
76% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. IPXL: 33.17 )
Ranked among companies with meaningful POCF only.
IPXL' s POCF Range Over the Past 10 Years
Min: 3.3  Med: 13.07 Max: 4004
Current: 33.17
3.3
4004
EV-to-EBIT 28.04
IPXL's EV-to-EBIT is ranked lower than
67% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. IPXL: 28.04 )
Ranked among companies with meaningful EV-to-EBIT only.
IPXL' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 10.00 Max: 760.7
Current: 28.04
1.8
760.7
EV-to-EBITDA 15.55
IPXL's EV-to-EBITDA is ranked higher than
51% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. IPXL: 15.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
IPXL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.7  Med: 7.00 Max: 51.9
Current: 15.55
1.7
51.9
Shiller P/E 25.84
IPXL's Shiller P/E is ranked higher than
72% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.10 vs. IPXL: 25.84 )
Ranked among companies with meaningful Shiller P/E only.
IPXL' s Shiller P/E Range Over the Past 10 Years
Min: 18.6  Med: 30.63 Max: 506.2
Current: 25.84
18.6
506.2
Current Ratio 2.52
IPXL's Current Ratio is ranked higher than
52% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. IPXL: 2.52 )
Ranked among companies with meaningful Current Ratio only.
IPXL' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 3.63 Max: 5.64
Current: 2.52
0.34
5.64
Quick Ratio 2.13
IPXL's Quick Ratio is ranked higher than
57% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. IPXL: 2.13 )
Ranked among companies with meaningful Quick Ratio only.
IPXL' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 3.14 Max: 5.19
Current: 2.13
0.34
5.19
Days Inventory 83.48
IPXL's Days Inventory is ranked higher than
68% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. IPXL: 83.48 )
Ranked among companies with meaningful Days Inventory only.
IPXL' s Days Inventory Range Over the Past 10 Years
Min: 50.25  Med: 90.64 Max: 162.44
Current: 83.48
50.25
162.44
Days Sales Outstanding 137.63
IPXL's Days Sales Outstanding is ranked lower than
82% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. IPXL: 137.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.05  Med: 77.94 Max: 189.27
Current: 137.63
34.05
189.27
Days Payable 40.46
IPXL's Days Payable is ranked lower than
78% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. IPXL: 40.46 )
Ranked among companies with meaningful Days Payable only.
IPXL' s Days Payable Range Over the Past 10 Years
Min: 20.18  Med: 45.55 Max: 189.99
Current: 40.46
20.18
189.99

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.38
IPXL's Price/Tangible Book is ranked lower than
85% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. IPXL: 9.38 )
Ranked among companies with meaningful Price/Tangible Book only.
IPXL' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.27  Med: 4.51 Max: 56.39
Current: 9.38
2.27
56.39
Price/Projected FCF 1.68
IPXL's Price/Projected FCF is ranked higher than
65% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. IPXL: 1.68 )
Ranked among companies with meaningful Price/Projected FCF only.
IPXL' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.62 Max: 3.37
Current: 1.68
1.05
3.37
Price/Median PS Value 1.04
IPXL's Price/Median PS Value is ranked higher than
56% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. IPXL: 1.04 )
Ranked among companies with meaningful Price/Median PS Value only.
IPXL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 1.39 Max: 32
Current: 1.04
0.58
32
Price/Graham Number 5.03
IPXL's Price/Graham Number is ranked lower than
84% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. IPXL: 5.03 )
Ranked among companies with meaningful Price/Graham Number only.
IPXL' s Price/Graham Number Range Over the Past 10 Years
Min: 0.48  Med: 1.53 Max: 6.61
Current: 5.03
0.48
6.61
Earnings Yield (Greenblatt) (%) 3.60
IPXL's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. IPXL: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPXL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 10.00 Max: 56
Current: 3.6
0.1
56
Forward Rate of Return (Yacktman) (%) -13.75
IPXL's Forward Rate of Return (Yacktman) (%) is ranked lower than
84% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. IPXL: -13.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IPXL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -21.8  Med: 2.10 Max: 90.5
Current: -13.75
-21.8
90.5

More Statistics

Revenue(Mil) $860
EPS $ 0.53
Beta1.20
Short Percentage of Float10.63%
52-Week Range $29.66 - 51.42
Shares Outstanding(Mil)72.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1,027 1,084 1,159
EPS($) 1.91 2.24 2.75
EPS without NRI($) 1.91 2.24 2.75

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:SHSE:600521, SZSE:000999, HKSE:00867, SHSE:600079, TSE:4516, SZSE:002038 » details
Traded in other countries:ILR.Germany,
Impax Laboratories Inc is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product develop
» More Articles for NAS:IPXL

Headlines

Articles On GuruFocus.com
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Nov 27 2015 
Kyle Bass Goes Fishing for These 3 New Holdings Nov 26 2015 
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 

More From Other Websites
Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference May 04 2016
Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference May 04 2016
Former Shkreli firm responsible for 5,000% drug hike sued May 02 2016
Impax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : May 2,... May 02 2016
Impax to Report First Quarter 2016 Results on May 10, 2016 Apr 18 2016
Impax to Report First Quarter 2016 Results on May 10, 2016 Apr 18 2016
Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and Michael Markbreiter from its Board of... Apr 14 2016
Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and Michael Markbreiter from its Board of... Apr 14 2016
Impax Announces Availability of EMVERM™ (mebendazole) Chewable Tablets, 100 mg Apr 13 2016
Impax Announces Availability of EMVERM™ (mebendazole) Chewable Tablets, 100 mg Apr 13 2016
4 More Good 'Chicken Shorts' Apr 08 2016
Impax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : April 7,... Apr 07 2016
[$$] FTC Sues Endo, Alleges Company Paid Off Generic Drugmakers Mar 31 2016
[$$] FTC Accuses Endo of Paying Off Generic Drugmakers Mar 31 2016
FTC accuses Endo, other drugmakers of antitrust violations Mar 31 2016
FTC accuses Endo, other drugmakers of antitrust violations Mar 31 2016
FTC files 'pay-for-delay' complaint against drug maker Endo Mar 31 2016
Allergan Broke Antitrust Laws With Endo Drug Deal, U.S. Says Mar 31 2016
U.S. FTC sues Endo for violating antitrust laws Mar 31 2016
Impax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : March 15, 2016 Mar 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK